Vanta BioscienceShare price, financial results, shareholding and management
- Market cap
- ₹16 cr
- Stock P/E
- 144.9peers 69.7
- Book value
- ₹29.8
- Price to book
- 0.75
- EV / operating profit
- -
- Market cap to sales
- 8.74
- ROCE · FY26
- 1.1%
- ROE · FY26
- 0.7%
- ROE, 3-year average
- -51.9%
- Operating margin · FY26
- 56.1%peers 10.4%
- Sales growth, 3 years
- -33.8%
- Profit growth, 3 years
- -
- Debt to equity
- 1.80peers 0.08
- Borrowings
- ₹38.1 cr
- Interest cover
- 1.0×
- Cash from business / op. profit
- -512%
- Debtor days
- 513
- Pledged
- 0.00%
- Promoter holding
- 72.81%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 426
- 52-week high / low
- ₹29 / ₹15
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
newboard is reading this company's filings. Its plain description, key points, management and study will appear here soon; the figures below are worked out from what it has filed.
Vanta Bioscience share price chart
Close on 6 Nov 2026 · +9.91% on the day · Vol 750
Daily prices to 6 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 6 Nov 2026
- 1 month
- +9.7%
- 3 months
- +3.0%
- 6 months
- +43.8%
- 1 year
- -19.1%
- Traded a day, 20 days
- ₹0.00 cr
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | -7% | - |
| 3 years, a year | -34% | - |
| Latest half, H2 FY26 | +62% | - |
Vanta Bioscience revenue and profit growth
Half-yearly results · Profit and lossSales have fallen.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before.
Vanta Bioscience half-yearly results
SME companies report every six months · ₹ crore
| H1FY23 | H2FY23 | H1FY24 | H2FY24 | H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 2.82 | 3.45 | 6.18 | 3.55 | 1.03 | 0.93 | 0.30 | 1.51 |
| Expenses | 3.37 | 5.30 | 4.11 | 4.30 | 1.41 | 4.81 | 0.67 | -0.13 |
| Operating profit | -0.55 | -1.85 | 2.06 | -0.75 | -0.38 | -3.87 | -0.37 | 1.64 |
| OPM | -19.5% | -53.5% | 33.4% | -21.2% | -37.0% | -415.2% | -121.8% | 108.3% |
| Interest | 2.48 | 3.40 | 2.85 | 2.90 | 2.14 | 1.92 | 0.88 | 0.10 |
| Depreciation | 1.31 | 1.36 | 1.54 | 2.95 | 1.69 | 2.73 | 0.61 | 0.23 |
| Profit before tax | -4.33 | -5.93 | -2.30 | -6.53 | -4.18 | -8.45 | -1.87 | 1.88 |
| Net profit | -2.56 | -6.02 | -2.28 | -6.33 | -4.13 | -9.16 | -1.82 | 1.93 |
Vanta Bioscience profit and loss
Full years to March, FY18 to FY26 · ₹ crore, consolidated where reported
| FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.88 | 12.08 | 13.75 | 9.82 | 9.40 | 6.28 | 9.72 | 1.96 | 1.82 |
| Expenses | 2.84 | 8.81 | 9.38 | 5.87 | 5.93 | 8.67 | 8.41 | 6.22 | 0.80 |
| Operating profit | 1.04 | 3.27 | 4.37 | 3.95 | 3.47 | -2.39 | 1.31 | -4.26 | 1.02 |
| OPM | 26.8% | 27.1% | 31.8% | 40.2% | 36.9% | -38.1% | 13.5% | -216.7% | 56.1% |
| Other income | 0.05 | 0.23 | 0.11 | 0.03 | 0.42 | 0.69 | 0.11 | 0.11 | 0.16 |
| Interest | 0.20 | 1.69 | 1.95 | 2.14 | 2.35 | 5.89 | 5.75 | 4.07 | 0.78 |
| Depreciation | 0.57 | 0.71 | 1.19 | 1.25 | 1.32 | 2.67 | 4.50 | 4.42 | 0.39 |
| Profit before tax | 0.32 | 1.10 | 1.34 | 0.59 | 0.22 | -10.26 | -8.83 | -12.63 | 0.01 |
| Tax rate | 90.6% | 36.4% | 24.6% | 23.7% | 40.9% | -1.8% | 2.5% | -5.2% | -678.6% |
| Net profit | 0.03 | 0.70 | 1.01 | 0.45 | 0.14 | -10.45 | -8.61 | -13.29 | 0.11 |
| EPS ₹ | 0.05 | 1.11 | 1.58 | 0.71 | 0.14 | -10.27 | -3.67 | -7.56 | 0.15 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
A tax rate above 60% or below zero (FY18, FY23, FY25, FY26) comes from tax charged on a small or negative profit, as reported.
Earnings per share before FY19 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.
Vanta Bioscience profitability
Margins and returns on capitalLast year the company kept more from each rupee of sales than the year before. It earns a low return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating margin | 26.8% | 27.1% | 31.8% | 40.2% | 36.9% | -38.1% | 13.5% | -216.7% | 56.1% |
| Tax rate | 90.6% | 36.4% | 24.6% | 23.7% | 40.9% | -1.8% | 2.5% | -5.2% | -678.6% |
| ROCE | · | 8.8% | 8.6% | 5.4% | 4.0% | -6.1% | -4.1% | -10.9% | 1.1% |
| ROE | · | 3.6% | 4.4% | 1.9% | 0.6% | -50.3% | -52.6% | -103.7% | 0.7% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Vanta Bioscience debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. It cut its borrowings last year. Its loans are now larger than its own money. Last year the business used more cash than it brought in. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.
Bars below the line are cash going out.
Vanta Bioscience balance sheet
At each 31 March · ₹ crore
| FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 5.73 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 7.11 |
| Reserves | 10.86 | 15.94 | 17.16 | 17.61 | 17.70 | 11.20 | 8.89 | 4.11 | 14.06 |
| Net worth | 16.59 | 22.25 | 23.47 | 23.92 | 24.01 | 17.51 | 15.20 | 10.42 | 21.17 |
| Borrowings | 11.18 | 13.25 | 17.37 | 35.97 | 44.86 | 57.16 | 60.96 | 70.09 | 38.08 |
| Other liabilities | 1.40 | 3.51 | 7.74 | 9.74 | 12.53 | 10.04 | 9.24 | 5.37 | 6.85 |
| Total liabilities | 29.17 | 39.01 | 48.58 | 69.63 | 81.40 | 84.71 | 85.40 | 85.88 | 66.10 |
| Fixed assets | 17.49 | 17.90 | 20.76 | 29.39 | 36.12 | 57.22 | 54.15 | 55.50 | 48.08 |
| Capital work in progress | 2.34 | 3.70 | 7 | 19.34 | 28.47 | 10.60 | 12.53 | 13.47 | 0 |
| Investments | 4.50 | 1.95 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Other assets | 4.84 | 15.46 | 20.82 | 20.90 | 16.81 | 16.89 | 18.72 | 16.91 | 15.02 |
Vanta Bioscience cash flow
₹ crore
| FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -6.75 | -1.04 | 2.34 | 6.97 | 5.28 | -0.63 | 2.68 | -2.41 | -5.22 |
| Cash from investing | -7.53 | -5.73 | -7.59 | -22.30 | -17.24 | -5.91 | -3.31 | -6.69 | -6.87 |
| Cash from financing | 13.93 | 9.94 | 2.17 | 17.78 | 9.53 | 6.41 | 0.69 | 9.16 | 12.08 |
| Net cash flow | -0.35 | 3.17 | -3.08 | 2.45 | -2.43 | -0.13 | 0.06 | 0.06 | -0.01 |
Working capital
Days
| FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 31 | 47 | 37 | 75 | 44 | 123 | 118 | 466 | 513 |
| Inventory days | 3,445 | · | · | · | · | · | · | 2,400 | · |
| Days payable | 228 | · | · | · | · | · | · | 1,821 | · |
| Cash conversion cycle | 3,248 | 47 | 37 | 75 | 44 | 123 | 118 | 1,044 | 513 |
| Working capital days | 190 | 261 | 260 | 91 | -135 | -163 | -217 | -2,127 | 435 |
Vanta Bioscience peers and competitors
Listed SME companies in the same industryBy sales, Vanta Bioscience is number 22 of the 23 listed SME companies in healthcare services.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Maitreya Medicare | 80 | - | 44.9 | -2.5 | -0.7% | 0.80 |
| Invicta Diagnostic | 84 | 17.3 | 32.4 | 4.9 | 30.2% | 0.07 |
| Nidan Laboratories and Healthcare | 19 | 12.4 | 25.5 | 1.5 | 19.0% | 0.16 |
| Aatmaj Healthcare | 50 | 69.7 | 24.3 | 0.7 | 9.7% | 0.41 |
| Aashka Hospitals | 243 | 72.8 | 23 | 3.3 | 22.8% | 0.08 |
| Clinitech Laboratory | 7 | 17.4 | 9.5 | 0.4 | 10.4% | 0.06 |
| KK Shah Hospitals | 31 | - | 9.3 | -0.6 | 8.3% | 0.00 |
| Broach Lifecare Hospital | 8 | 94.4 | 6 | 0.1 | 8.5% | 0.00 |
| Dr Lalchandani Labs | 6 | 104.9 | 4.2 | 0.1 | 16.5% | 0.15 |
| Vanta Bioscience | 16 | 144.9 | 1.8 | 0.1 | 56.1% | 1.80 |
| Global Longlife Hospital and Research | 14 | - | 0 | -1.7 | - | 0.00 |
| Median of the 10 others | 25 | 69.7 | 16.3 | 0.3 | 10.4% | 0.08 |
Vanta Bioscience shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company, a little more than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders is about the same.
Vanta Bioscience shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Mar 23 | Sep 23 | Mar 24 | Sep 24 | Mar 25 | May 25 | Sep 25 | Mar 26 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 69.36% | 69.36% | 69.36% | 69.36% | 69.36% | 72.81% | 72.81% | 72.81% |
| Number of shareholders | 394 | 388 | 418 | 424 | 408 | 408 | 419 | 426 |
Vanta Bioscience latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹1.5 cr (+62%), net profit ₹1.9 cr (-) on H2 FY25.
- Shareholding, 31 March 2026: promoters unchanged at 72.81%.
Vanta Bioscience announcements
4 on record, latest first; each opens the filing on the exchange
- AGM/EGMSubmission of AGM Proceedings, Voting Results and Scrutinizers Report for the 10th Annual General MeetingPDF ↗
- AGM/EGMSubmission of AGM Proceedings, Voting Results and Scrutinizer''s Report for the 10th AGMPDF ↗
- Insider Trading / SASTClosure of Trading WindowPDF ↗
- OthersAnnual Report for FY 2025-26PDF ↗
Vanta Bioscience annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
Vanta Bioscience share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Vanta Bioscience's data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- iThe shares traded on only 116 days in the past year, so the price, its range and the returns here rest on few trades.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (71,12,000 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY18 to FY26.
- iPrices run to the close on 6 Oct 2026, from the exchange's daily figures.
Questions people ask about Vanta Bioscience
What does Vanta Bioscience do?
Vanta Bioscience is an SME company listed on BSE SME, in healthcare services.
What is the share price of Vanta Bioscience?
₹22.4 at the close on 6 Nov 2026, from the exchange's daily figures.
What is the market cap of Vanta Bioscience?
₹16 cr at the close on 6 Nov 2026, on 71,12,000 shares.
What is the P/E of Vanta Bioscience?
144.9 times FY26 profit at the close on 6 Nov 2026 (our arithmetic).
What are Vanta Bioscience's revenue and profit?
Revenue ₹2 cr and profit after tax ₹0 cr in FY26.
Who are the promoters of Vanta Bioscience?
The promoter group; promoters held 72.81% at 31 March 2026.
What is Vanta Bioscience's website?
www.vantabio.com
More SME companies like Vanta Bioscience
Other listed SME companies in healthcare services, the closest in size first, each read from its own documents.
- Global Longlife Hospital and ResearchGLHRL · BSE SME · Healthcare ServicesMarket cap ₹15 cr
- Nidan Laboratories and HealthcareNIDAN · NSE Emerge · Healthcare Services · listed 2021Market cap ₹17 cr
- KK Shah HospitalsKKSHL · BSE SME · Healthcare ServicesMarket cap ₹31 cr
- Broach Lifecare HospitalBROACH · BSE SME · Healthcare ServicesMarket cap ₹8 cr
- Clinitech LaboratoryCTLLAB · BSE SME · Healthcare ServicesMarket cap ₹7 cr
- Dr Lalchandani LabsDLCL · BSE SME · Healthcare ServicesMarket cap ₹6 cr
Built from 4 exchange announcements, 8 shareholding patterns and 9 years of reported results. Every figure carries its source; where the documents are silent, the page says so.